Tech Profiles

Browse More

Product Specials

Dr. Peter Geistlich Receives 2014 Distinguished Humanitarian Award from Loma Linda University

Posted on July 22, 2014

PRINCETON, NJ, July 22, 2014 /PRNewswire/ -- Geistlich Pharma North America is pleased to announce that Dr. Peter Geistlich, Chairman of the Board, Geistlich Pharma AG was presented with Loma Linda University's Distinguished Humanitarian Award on May 25, 2014.

The award recognized Dr. Geistlich as an "internationally renowned pioneer in materials research, global leader in regenerative medicine, and passionate advocate for high quality research and education that translate into improved patient outcomes.  His generous philanthropic engagement supports advancement of the University's model 'to make man whole'".

Dr. Geistlich shares an enduring and vibrant bond with the University, built through decades of scientific collaboration with Professor Philip Boyne.  Together, their commitment to advancing quality of care in the fields of oral and maxillofacial surgery and tissue regeneration led to the joint creation and the funding of the Boyne-Geistlich Professorship in Oral and Maxillofacial Surgery at The School of Dentistry.

"It is a highlight in my life to be honored by this very fine university and to have had the opportunity to collaborate on research projects for many years with Dr. Philip Boyne and now with Dr. Alan Herford. For me it is a joy to participate in and to support quality research. I have always been very impressed with the innovative research activities and the quality results that the Loma Linda University School of Dentistry has generated," said Dr. Peter Geistlich, Chairman of the Board, Geistlich AG.

"The company is very thankful and proud of Dr. Geistlich's many accomplishments.  It is through the collaboration with Dr. Phillip Boyne and Loma Linda University that many of our product innovations were born.  The result has been scientifically proven products that have helped millions of dentists and their patients worldwide," said Mr. Greg Bosch, CEO, Geistlich Pharma North America.